Article
In vitro blood cell responsiveness to IFN-α predicts clinical response independently of IL28B in hepatitis C virus genotype 1 infected patients.
Journal of translational medicine - 21 Jul 2014
Bourke Nollaig M, O'Neill Mary-Teresa, Sarwar Shahzad, Norris Suzanne, Stewart Stephen, Hegarty John E, Stevenson Nigel J, O'Farrelly Cliona
Abstract excerpt
BACKGROUND: Treatment with interferon-alpha (IFN-α) and ribavirin successfully clears hepatitis C virus (HCV) infection in 50% of patients infected with genotype 1. Addition of NS3-4A protease inhibitors (PIs) increases response rates but results in additional side effects and significant economic costs. Here, we hypothesised that in vitro responsiveness of peripheral blood mononuclear cells (PBMCs) to IFN-α...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.